User:Ghula Alie/sandbox
David Boulware | |
|---|---|
| Born | David R Boulware 1974 (age 49–50) |
| Nationality | American |
| Citizenship | American, British |
| Alma mater | Wabash College (Bachelor of Science), Indiana University School of Medicine (Doctor of Medicine), University of Minnesota (Master of Public Health) |
| Occupation | Physician infectious diseases (medical specialty) |
| Years active | 2004—present |
| Known for | Covid-19 researcher |
| Title | Professor of Medicine at University of Minnesota |
David Boulware is a Professor of Medicine with tenture and a practicing infectious disease physician at the University of Minnesota Medical School. He is a member of the graduate faculty for the University of Minnesota School of Public Health Epidemiology PhD program and for the Microbiology, Immunology, and Cancer Biology (MICaB) graduate program. Boulware was the first Lois & Richard Distinguished Assistant Professorship at the University of Minnesota. Boulware is an active medical researcher engaged in clinical trials in infectious diseases.[1]
Early life and education
[edit]Boulware attended Wabash College followed by Indiana University School of Medicine for medical school and then at the University of Minnesota Medical School for an internal medicine & pediatrics residency training followed by an infectious diseases fellowship.
Career
[edit]Boulware's primary research has been focused on improving the diagnosis, prevention, and treatment of cryptococcal meningitis.[2] However, he is best known for outpatient Covid-19 clinical trials.
Boulware's team rapidly launched a series of three U.S. nationwide randomized clinical trials testing hydroxychloroquine for post-exposure prophylaxis, early treatment, and pre-exposure prophylaxis for prevention of COVID-19 on March 17, 2020.[3] These were among the first U.S. trials to be launched.[4] The pre-exposure prophylaxis trial was reported June 3, 2020 showing that taking hydroxychloroquine was not effective at preventing Covid-19.[5][6][7] As described, "To say that the recruitment of this post-exposure prophylaxis trial was innovative hardly gives the methods enough credit."[8] These trials were pioneering for being remote internet-based randomzied clinical trials.[9][10]
The hydroxychloroquine early treament trial was the first large phase III, outpatient randomized clinical trial testing an outpatient therapy for Covid-19.[11][12]
While pre-exposure prophylaxis with hydroxychloroquine for prevention was promoted on May 18, 2020,[13] the subsequent randomized trial did not show any benefit.[14]
Boulware served as senior investigator on other trials testing early treatements for covid-19 including the TogetherTrial ivermectin;[15][16], which demonstrated that ivermectin did not have a clinical benefit for early Covid-19.[17] University of Minnesota's Covid-Out randomized trial testing metformin, ivermectin, and fluvoxamine.[18] In December 2021, Boulware took the initiate to apply to the U.S. FDA for an Emergency Use Authorization for fluvoxamine 100mg twice daily.[19]
Boulware serves as the national co-chair of the trial steering committee for the NIH ACTIV-6 platform clinical trial testing repurposed medicines for COVID-19.[20][21]
Notable Contributions and Honors
[edit]- World Health Organization 2017 Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy[22]
- World Health Organization 2018 Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children[23]
- US Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV -- guideline committee member [24]
- American Society for Clinical Investigation, honorary medicine society elected member 2020.[25]
References
[edit]- ^ "David R Boulware". University of Minnesota.
- ^ Adams, Patrick (4 January 2016). "Crushing Crypto, the deadly, neglected disease that kills 300K every year". Newsweek.
- ^ Boulware, David R.; Pullen, Matthew F.; Bangdiwala, Ananta S.; Pastick, Katelyn A.; Lofgren, Sarah M.; Okafor, Elizabeth C.; Skipper, Caleb P.; Nascene, Alanna A.; Nicol, Melanie R.; Abassi, Mahsa; Engen, Nicole W.; Cheng, Matthew P.; LaBar, Derek; Lother, Sylvain A.; MacKenzie, Lauren J.; Drobot, Glen; Marten, Nicole; Zarychanski, Ryan; Kelly, Lauren E.; Schwartz, Ilan S.; McDonald, Emily G.; Rajasingham, Radha; Lee, Todd C.; Hullsiek, Kathy H. (6 August 2020). "A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19". New England Journal of Medicine. 383 (6): 517–525. doi:10.1056/NEJMoa2016638.
- ^ Palca, Joe (31 March 2020). "Clinical Trials Set To Determine If Anti-Malaria Drug Effective Against COVID-19". NPR.
- ^ Grady, Denise (3 June 2020). "Malaria Drug Promoted by Trump Did Not Prevent Covid Infections, Study Finds". The New York Times.
- ^ "Hydroxychloroquine, a drug promoted by Trump, failed to prevent healthy people from getting covid-19 in trial". Washington Post.
- ^ "White House asked for Dr. Boulware's advice on hydroxychloroquine. This is what he said - CNN Video". CNN.
- ^ Sax, Paul (7 June 2020). "Hydroxychloroquine Not Effective in Preventing COVID-19 -- In Praise of a Negative Clinical Trial". HIV and ID Observations. NEJM Journal Watch.
- ^ Adam, Rogers. "The Strange and Twisted Tale of Hydroxychloroquine". Wired.
- ^ "How to Conduct a Clinical Trial During a Pandemic—An Interview with Dr. David Boulware". Open Forum Infectious Diseases. 7 (7): ofaa277. 1 July 2020. doi:10.1093/ofid/ofaa277.
- ^ "Hydroxychloroquine studies show drug is not effective for early treatment of mild covid-19". Washington Post.
- ^ Skipper, Caleb P.; Pastick, Katelyn A.; Engen, Nicole W.; Bangdiwala, Ananta S.; Abassi, Mahsa; Lofgren, Sarah M.; Williams, Darlisha A.; Okafor, Elizabeth C.; Pullen, Matthew F.; Nicol, Melanie R.; Nascene, Alanna A.; Hullsiek, Kathy H.; Cheng, Matthew P.; Luke, Darlette; Lother, Sylvain A.; MacKenzie, Lauren J.; Drobot, Glen; Kelly, Lauren E.; Schwartz, Ilan S.; Zarychanski, Ryan; McDonald, Emily G.; Lee, Todd C.; Rajasingham, Radha; Boulware, David R. (20 October 2020). "Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial". Annals of Internal Medicine. 173 (8): 623–631. doi:10.7326/M20-4207.
- ^ McDonald, Jessica; Rieder, Rem (21 May 2020). "Trump Misleads on Hydroxychloroquine, Again". FactCheck.org.
- ^ Rajasingham, Radha; Bangdiwala, Ananta S; Nicol, Melanie R; Skipper, Caleb P; Pastick, Katelyn A; Axelrod, Margaret L; Pullen, Matthew F; Nascene, Alanna A; Williams, Darlisha A; Engen, Nicole W; Okafor, Elizabeth C; Rini, Brian I; Mayer, Ingrid A; McDonald, Emily G; Lee, Todd C; Li, Peter; MacKenzie, Lauren J; Balko, Justin M; Dunlop, Stephen J; Hullsiek, Katherine H; Boulware, David R; Lofgren, Sarah M; Abassi, Mahsa; Balster, Andrew; Collins, Lindsey B; Drobot, Glen; Krakower, Douglas S; Lother, Sylvain A; MacKay, Dylan S; Meyer-Mueller, Cameron; Selinsky, Stephen; Solvason, Dayna; Zarychanski, Ryan; Zash, Rebecca (1 June 2021). "Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial". Clinical Infectious Diseases. 72 (11): e835–e843. doi:10.1093/cid/ciaa1571.
- ^ "TOGETHER Trial". TOGETHER Trial.
- ^ Reis, Gilmar; Silva, Eduardo A.S.M.; Silva, Daniela C.M.; Thabane, Lehana; Milagres, Aline C.; Ferreira, Thiago S.; dos Santos, Castilho V.Q.; Campos, Vitoria H.S.; Nogueira, Ana M.R.; de Almeida, Ana P.F.G.; Callegari, Eduardo D.; Neto, Adhemar D.F.; Savassi, Leonardo C.M.; Simplicio, Maria I.C.; Ribeiro, Luciene B.; Oliveira, Rosemary; Harari, Ofir; Forrest, Jamie I.; Ruton, Hinda; Sprague, Sheila; McKay, Paula; Guo, Christina M.; Rowland-Yeo, Karen; Guyatt, Gordon H.; Boulware, David R.; Rayner, Craig R.; Mills, Edward J. (5 May 2022). "Effect of Early Treatment with Ivermectin among Patients with Covid-19". New England Journal of Medicine. 386 (18): 1721–1731. doi:10.1056/NEJMoa2115869.
- ^ Zimmer, Carl (30 March 2022). "Ivermectin Does Not Reduce Risk of Covid Hospitalization, Large Study Finds". The New York Times.
- ^ "COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)". ClinicalTrials.gov. clinicaltrials.gov. 2 March 2022.
- ^ "Doctor Submits Fluvoxamine EUA Application to FDA". www.medpagetoday.com. 29 December 2021.
- ^ "Activ-6 Study".
- ^ "ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications". clinicaltrials.gov. 22 March 2022.
- ^ "Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy". www.who.int. World Health Organization.
- ^ "Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children". www.who.int. World Health Organization.
- ^ "US HHS/NIH/CDC HIV Opportunistic Infection Guidelines | NIH". clinicalinfo.hiv.gov. US HHS.
- ^ "David R. Boulware, MD, MPH". The American Society for Clinical Investigation.
External links
[edit]- Ghula Alie/sandbox publications indexed by Google Scholar